Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Media contact

Media contact

Oxurion is committed and engaged to communicate openly with all relevant stakeholders. Regarding any press enquiries, comments or questions about Oxurion, please contact our Corporate Communications department:

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com

Media Center

Easy accessible and always available, the Oxurion Media Center is your access point for Oxurion related AV assets. Feel free to register and download any material you may need.

Oxurion Media Center

The materials (such as images, photographs, illustrations, icons, texts, video clips, written and other proprietary information) contained in this Media Center (the “Materials”) are the valuable property of ThromboGenics NV and/or its licensors. ThromboGenics and/or its licensors, as appropriate, reserve all patent, copyright and other proprietary rights to the Materials, including all design, manufacturing, reproduction, use, and sales rights thereto. You may download, print and use the Materials solely for the permitted purpose as specified in the respective “Asset Details” or – if ThromboGenics provides you with a download link – for any purpose, provided you do not delete or change any copyright or trademark, or distort, mutilate or otherwise modify the proprietary information in a manner that may be prejudicial to ThromboGenics or its licensors. To allow for design, content and specification improvements, the Materials in this Media Center are subject to change at any time, without notice. Reproduction of this Media Center or portions thereof without prior written approval of ThromboGenics is prohibited.